Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesse Green

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
HIV Clinical Trials|June 29, 2005
Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in ItalyJohn Hornberger, Jesse Green, Neil Wintfeld, et al.
Pharmacoeconomics|February 21, 2004
Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis CSean D Sullivan, Antonio Craxi, Alfredo Alberti, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 13, 2006
Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infectionJohn Hornberger, Francesca J Torriani, Douglas T Dieterich, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 18, 2008
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records reviewIngo J Diel, Rudolf Weide, Hubert Köppler, et al.
Journal of Cancer Research and Therapeutics|May 19, 2010
Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records reviewRudolf Weide, Hubert Koppler, Lucia Antras, et al.
Journal of Hepatology|March 20, 2004
The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis CTarek Hassanein, Graham Cooksley, Mark Sulkowski, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 6, 2025
Efficacy of Etrasimod in Ulcerative Colitis: Analysis of ELEVATE UC 52 and ELEVATE UC 12 by Baseline Endoscopic SeverityAndres J Yarur, Walter Reinisch, Shannon Chang, et al.
Journal of Gastroenterology and Hepatology|March 3, 2006
Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of lifeSanjeev Arora, Christopher O'Brien, Stefan Zeuzem, et al.
Pharmacoeconomics|March 12, 2003
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis CJens Rasenack, Stefan Zeuzem, S Victor Feinman, et al.
Journal of Crohn'S & Colitis|May 3, 2024
Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical ProgrammeMiguel Regueiro, Britta Siegmund, Andres J Yarur, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
HIV Clinical Trials|June 29, 2005
Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in ItalyJohn Hornberger, Jesse Green, Neil Wintfeld, et al.
Pharmacoeconomics|February 21, 2004
Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis CSean D Sullivan, Antonio Craxi, Alfredo Alberti, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 13, 2006
Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infectionJohn Hornberger, Francesca J Torriani, Douglas T Dieterich, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 18, 2008
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records reviewIngo J Diel, Rudolf Weide, Hubert Köppler, et al.
Journal of Cancer Research and Therapeutics|May 19, 2010
Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records reviewRudolf Weide, Hubert Koppler, Lucia Antras, et al.
Journal of Hepatology|March 20, 2004
The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis CTarek Hassanein, Graham Cooksley, Mark Sulkowski, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 6, 2025
Efficacy of Etrasimod in Ulcerative Colitis: Analysis of ELEVATE UC 52 and ELEVATE UC 12 by Baseline Endoscopic SeverityAndres J Yarur, Walter Reinisch, Shannon Chang, et al.
Journal of Gastroenterology and Hepatology|March 3, 2006
Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of lifeSanjeev Arora, Christopher O'Brien, Stefan Zeuzem, et al.
Pharmacoeconomics|March 12, 2003
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis CJens Rasenack, Stefan Zeuzem, S Victor Feinman, et al.
Journal of Crohn'S & Colitis|May 3, 2024
Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical ProgrammeMiguel Regueiro, Britta Siegmund, Andres J Yarur, et al.
Pageof 3